OUNCE SACHS

INSTITUTIONAL INVESTOR PRESENTATION

Private capital discussion | Institutional investors | August 2026

02 INVESTMENT THESIS

A developed IP portfolio entering institutional commercial execution.

A proprietary healthcare and consumer IP platform converting founder-funded formulations, brands and technical work into regulated, manufactured and commercially active products.

Built before capital

More than US$4M has been invested into formulations, scientific validation, regulatory development, brand architecture, product design and commercial infrastructure.

IP-led platform

The company combines proprietary formulations, know-how, technical work product, trademarks, domains and product architecture across three commercial propositions.

Capital conversion

The financing is intended to fund regulatory execution, manufacturing readiness, inventory, commercial appointments, market activation and working capital.

03 INSTITUTIONAL SNAPSHOT

The first five minutes should be simple: developed IP, independent valuation, founder-funded de-risking and commercial conversion.

The investor proposition is not a concept-stage product story; it is a staged conversion of developed assets into revenue-producing channels.

$37.65M	$0.0753	>US$4M	~72%
INDICATIVE EQUITY VALUE	**INDICATIVE VALUE PER SHARE**	**FOUNDER INVESTMENT**	**MANAGEMENT TARGET GROSS MARGIN**
Independent valuation reference point	Based on 500M shares outstanding	Development capital invested to date	Management planning assumption

All figures are subject to definitive transaction documentation, board approval, securities-counsel review and final due diligence.

04 PLATFORM

One institutional platform. Three commercial propositions.

A shared development base supports distinct route-to-market opportunities across healthcare, professional hygiene, premium consumer and family retail.

Brand	Role within group	Primary channels
MEDUSA	Scientific and institutional hygiene platform	Healthcare, institutional procurement, hospitality, professional hygiene, licensing and strategic supply.
HYGIACTIVIA	Premium consumer expression of the hygiene platform	Prestige retail, travel, hospitality, e-commerce, gifting and selected institutional partnerships.
POMME Kids	Family and child-focused hygiene proposition	Premium family retail, pharmacies, travel retail, e-commerce, licensing and collaborations.

05 BUILT ASSET BASE

The raise is intended to commercialise developed assets, not create the underlying portfolio.

The company has focused on asset creation, validation and international positioning before seeking institutional commercial execution capital.

01

Portfolio creation

Formulations, brand architecture, IP protection, product design and commercial documentation.

02

Validation and positioning

Scientific work, technical documentation, priority territories and commercial preparation.

03

Commercial conversion

Regulatory completion, manufacturing readiness, inventory, market entry and working capital.

06 INTELLECTUAL PROPERTY

Defensibility is built from science, formulation know-how and brand architecture.

The portfolio is not dependent on a single product image. It is supported by a combination of technical work, trade secrets, trademarks, domains and controlled commercial rights.

Asset category	Institutional relevance
Formulations and know-how	Core technical foundation for product performance, differentiation and future extensions.
Technical work product	Documentation, claims substantiation, product specifications and supplier requirements for regulated entry.
Brands and trademarks	MEDUSA, HYGIACTIVIA and POMME Kids create differentiated market propositions and licensing optionality.
Packaging and product architecture	Distinctive formats and product systems support premium positioning and channel separation.
Commercial rights and documentation	Licensing, distribution, supply and strategic partnership templates support scalable market entry.

07 INDEPENDENT VALUATION

Independent valuation provides a private-capital reference point.

The valuation frames investor discussion and is not presented as a current public-market trading price.

$37.65M	$0.0753	2 Aug 2026	RFR
INDICATIVE EQUITY VALUE	INDICATIVE VALUE PER SHARE	VALUATION DATE	METHODOLOGY
500,000,000 shares	Independent valuation basis	ABM Sanaullah & Co.	Relief-from-royalty

Final transaction terms, issuer structure, securities documentation and any future public-market transaction remain subject to legal, securities-counsel and board approval.

08 BUSINESS MODEL

Asset-light, IP-led and partnership-enabled.

Ounce Sachs intends to retain strategic control of high-value assets while using qualified third parties for manufacturing, testing, logistics and local distribution.

Revenue pathway	Role in model
Direct product margin	Controlled channels where brand economics and customer access justify direct involvement.
Wholesale supply	Commercial volume through distributors, retail channels and institutional customers.
Institutional contracts	Professional hygiene, healthcare, hospitality and strategic supply opportunities.
Territorial distribution	Local-market execution with partner-led entry and reduced operational risk.
Licensing / royalties	Longer-term monetisation of IP, product architecture and market-specific commercial rights.

09 MARKET ENTRY STRATEGY

GCC-first execution with repeatable territorial playbooks.

Initial commercial activity is expected to focus on Saudi Arabia and the wider GCC before selected international expansion.

Saudi Arabia	Priority launch market; first-year planning case assumes Q2 2027 launch, subject to funding and regulatory approvals.
Wider GCC	Regional expansion through distributor onboarding, institutional pilots and partner-led market activation.
Selected international markets	European, Hong Kong and US opportunities considered once regulatory, manufacturing and commercial playbooks are established.

10 CAPITAL DEPLOYMENT

Milestone-driven deployment over 18 to 24 months.

Capital is intended to finance commercial execution rather than standing-start product creation.

Phase	Timing	Primary use of capital
Foundation and readiness	Closing to Month 3	Corporate/IP consolidation, audit readiness, regulatory submissions, insurance, supplier contracting and key appointments.
Initial commercialisation	Months 3-9	Manufacturing validation, packaging, initial inventory, distributor onboarding, pilots and launch activation.
Scale and replenishment	Months 9-18+	Replenishment inventory, working capital, additional territories, product extensions and selective direct-channel investment.

Deployment remains staged, milestone-gated and liquidity-conscious.

11 FINANCIAL PLANNING CASE

Management forecast is based on phased portfolio launch.

The management planning case assumes a Saudi Arabia launch in Q2 2027, subject to funding, regulatory approvals and execution milestones, followed by phased GCC and selected international expansion.

US$15.0M	US$9.0M	US$3.5M	US$2.5M	~72%
FIRST-YEAR MANAGEMENT PLANNING CASE	**MEDUSA**	**HYGIACTIVIA**	**POMME KIDS**	**TARGET GM**
Management planning case	Institutional hygiene	Premium consumer	Family hygiene	Portfolio

Management planning case only; outcomes remain subject to funding, regulatory timing, launch assumptions, working-capital sensitivities and final due diligence.

12 CAPITAL STRATEGY

Initial institutional financing within a broader multi-stage capital programme.

The objective is to appoint a serious capital-markets partner and structure the first financing around commercial milestones and institutional execution.

Initial financing	Initial financing size to be determined with the appointed capital-markets partner, with current planning based on mid-single to low-double-digit growth capital.
Subsequent capital	Follow-on financings tied to execution milestones, commercial traction, governance development and public-market readiness.
Strategic objective	Build the institutional architecture intended to support a potential senior-market pathway over time.

Building the institutional architecture for scale.

Professional appointments are intended to strengthen reporting discipline, investor credibility and execution capacity as the commercial programme scales.

Function	Status / positioning
Capital-markets partner	To be appointed - intended to support institutional investor access and transaction structuring.
Securities counsel	To be appointed - offering documentation, securities-law review and public-market pathway.
Independent auditor	To be appointed - audit readiness, reporting discipline and institutional investor requirements.
Transfer agent	To be appointed - shareholder administration and potential public-market infrastructure.
Independent valuation adviser	ABM Sanaullah & Co. - independent private-capital valuation reference.

14 INVESTMENT CONSIDERATIONS

Key risks are execution-led and addressed through staged capital discipline.

The principal investor consideration is whether the developed asset base can be converted into a professionally managed, repeatable and capital-efficient commercial platform.

Area	Investor consideration	Mitigating approach
Near term	Financing close; IP consolidation; regulatory readiness; founder concentration.	Closing checklist, IP assignments/licences, milestone-based use of proceeds, management appointments and documented operating procedures.
Medium term	Manufacturing quality; working capital; distributor performance; customer concentration; product liability.	Qualified suppliers, quality agreements, conservative inventory, partner KPIs, insurance and channel diversification.
Long term	IP leakage; imitation; commoditisation; regulatory fragmentation; brand relevance.	Trade-secret controls, continuous innovation, portfolio expansion, selective registrations and territory-specific compliance.

A concise investment case for institutional review.

Ounce Sachs combines developed IP, independent valuation, commercial optionality and a defined path toward institutional capital-markets readiness.

Developed IP portfolio

Formulations, know-how, brands, product architecture and commercial documentation already created.

Independent valuation

US$37.65M indicative equity value and US$0.0753 indicative value per share.

Founder-funded asset creation

More than US$4M invested prior to institutional commercial execution.

Three commercial propositions

MEDUSA, HYGIACTIVIA and POMME Kids provide channel optionality from institutional hygiene to premium consumer and family retail.

Asset-light model

Strategic control of IP and brand; third parties for manufacturing, testing, logistics and local distribution.

Public-markets discipline

Governance, reporting, securities counsel and capital-markets infrastructure to support a potential senior-market pathway.

OUNCE SACHS

INSTITUTIONAL ENQUIRIES

Ounce Sachs Inc.